February 4, 2026 Biodexa Announces Exclusive License of Otsuka’s OPB-171775, a potent Phase 1 ready Molecular Glue for GIST ...
Dr. Breelyn Wilky explains how vague symptoms and testing challenges delay GIST diagnoses; however, molecular testing can help guides treatment decisions. Dr. Breelyn Wilky, an associate professor of ...
GISTs originate from interstitial cells of Cajal and are staged by size, location, mitotic rate, and genetic mutations, influencing treatment strategies. Diagnosis involves imaging, endoscopy, biopsy, ...
New Data Demonstrates Significant Reduction in Tumor Growth and KIT Expression in Preclinical GIST Models Induction of Tumor Cell Death – HT-KIT triggered significant tumor cell death as early as 24 ...
Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in ...
The FDA has granted breakthrough therapy designation (BTD) for bezuclastinib in combination with sunitinib (Sutent) for the ...
GSK plc (NYSE:GSK) agreed to acquire IDRx, Inc., a biopharmaceutical company focused on precision therapeutics for gastrointestinal stromal tumors (GIST), for $1 billion. Under the agreement, GSK ...
BLOOMINGTON, Minn.--The GIST Cancer Research Fundraiser is Friday, August 4 at the Knights of Columbus from 7:00 p.m.-10:00 p.m. Proceeds provide support to those with Gastro Intestinal Stromal Tumors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results